MedTrace Logo

Effectiveness and Safety of Spondylitis Related to Inflammatory Bowel Disease

NCT00972218 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2016-09-16

No results posted yet for this study

Summary

Adalimumab is an antibody treatment that targets and neutralizes a molecule produced in the body that is associated with inflammation, tumor necrosis factor (TNF). This molecule is an important factor in causing the inflammation seen in people with a form of inflammatory spinal arthritis called spondylitis as well as inflammation in the bowel called Crohn's disease. Spondylitis and Crohn's disease tend to go together and this study will assess to what degree this treatment is effective for those patients that have both disorders at the same time.

Conditions

Interventions

BIOLOGICAL

Adalimumab

Adalimumab subcutaneous injections 40 mg dose every other week for 24 weeks

Sponsors & Collaborators

  • Abbott

    collaborator INDUSTRY

  • University of Alberta

    lead OTHER

Principal Investigators

  • Walter P Maksymowych, FRCP(C) · University of Alberta

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2010-01-31
Completion
2010-01-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00972218 on ClinicalTrials.gov